Skip Ribbon Commands
Skip to main content
Menu
Dr Yeo Tianrong

Dr Yeo Tianrong

MBBS (NUS), MRCP (UK), MMED (NUS), MCI (NUS), FAMS (Neurology), FRCP (Edin), PhD (DPhil Oxford)

Senior Consultant

National Neuroscience Institute

Specialty: Neurology, Neurology

Clinical Interest: Neuroimmunology, General Neurology

Conditions Treated by this Doctor:
Autoimmune Encephalitis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder.

Clinical Appointments

  • Senior Consultant Department of Neurology National Neuroscience InstituteNational Neuroscience Institute
  • Deputy Director, Clinical Research Research (National Neuroscience Institute) National Neuroscience InstituteNational Neuroscience Institute

Profile

Dr Yeo Tianrong is a senior consultant neurologist and Deputy Director, Clinical Research at the National Neuroscience Institute (NNI). He also holds a position of Assistant Professor at both Duke-NUS Medical School and Lee Kong Chian School of Medicine and is the Deputy Director of Brain Bank Singapore.

Dr Yeo’s clinical and research interests are in neuroimmunological diseases. He provides both inpatient and outpatient clinical services, taking care of people with Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD), Autoimmune Encephalitis and other immune-mediated diseases of the central nervous system. In 2016, Dr Yeo was awarded the NMRC Research Fellowship Award to pursue a PhD at the University of Oxford, focusing on the use of metabolomics in neuroimmunological diseases for biomarker discovery in human cohorts and investigating the metabolic perturbations in animal models of neuroinflammation. His current research focus is on unravelling the molecular underpinnings in which host-environmental factors contribute to neuroinflammation, and in so doing, discover novel biomarkers and potential interventions to alleviate neuroinflammation. In line with this research theme, he was awarded the NMRC Transition Award in 2021 to investigate the gut microbiome and metabolome and their relationship with systemic and neuroinflammation in people with MS and NMOSD.

Dr Yeo has lectured and presented at major regional and international MS conferences. He is a member of the scientific committee for PACTRIMS (Pan-Asian Committee for the Treatment and Research in Multiple Sclerosis). Dr Yeo is also involved in the clinical and research training of medical students and residents, and has received several awards for his clinical work, research and education.

Education

  • PhD (DPhil Oxford), 2020
  • MCI (NUS), 2017
  • MMED Internal Medicine (NUS), 2012
  • MRCP (UK), 2011
  • MBBS (NUS), 2007

Professional Appointments and Committee Memberships

  • Senior Consultant, Department of Neurology, National Neuroscience Institute, Singapore
  • Visiting Consultant, Department of Neurology, Changi General Hospital, Singapore
  • Assistant Professor, Duke-NUS Medical School
  • Assistant Professor, Lee Kong Chian School of Medicine, Nanyang Technological University
  • Deputy Director, Clinical Research, National Neuroscience Institute
  • Deputy Director, Brain Bank Singapore
  • Clinical Lecturer (Yong Loo Lin School of Medicine, National University of Singapore)
  • Member, Scientific committee for PACTRIMS (Pan-Asian Committee for the Treatment and Research in Multiple Sclerosis), 2023 to present
  • Research Lead, Department of Neurology (NNI@TTSH), 2021 to 2023 
  • Member, NNI Tissue Bank Tissue Release Committee, 2021 to present
  • Deputy in charge, NNI Tissue Bank Neuroimmunology Collection, 2021 to present
  • Research Lead, NNI Neuroimmunology-Neuroinflammation Programme, 2020 to present
  • Editor, NNI Research Newsletter, 2020 to present
  • Member, Committee for APN (advanced practitioner nurse) Competence, NNI, 2020 to present
  • Member, FAMS (Neurology), 2016 to present
  • Member, Peer Review Learning Quality Assurance Committee, NNI, 2016 to present
  • Faculty, SingHealth Neurology Residency Program, 2015 to present  
  • Member, Clinical Neuroscience Society Singapore, 2012 to present
  • Member, SingHealth Infection Control and Audit (SICA) Task Force, 2015 to 2016
  • Member, SingHealth Infection Control and Prevention (SICP) Workgroup, 2015 to 2016
  • Treasurer, Clinical Neuroscience Society Singapore, 2015 to 2016

Awards

  • Singapore Health Quality Service Award, Star Award (SingHealth, 2024)
  • NNI Service Quality Award, Star Award (NNI, 2023)
  • COVID-19 Resilience Medal (MOH, 2023)
  • TTSH Antimicrobial Stewardship Programme, Antibiotic Guardian Award (TTSH, 2022)
  • NNI Service Quality Award, Gold Award (NNI, 2022)
  • Singapore Health Quality Service Award, Gold Award (SingHealth, 2022)
  • Singapore Health Quality Service Award, Silver Award (SingHealth, 2021)
  • Transition Award (NMRC, 2021)
  • SingHealth Duke-NUS Neuroscience ACP Research Paper of the Quarter (Jan – Jun 2020)
  • Educational Award (MSVirtual, 2020)
  • SingHealth Duke-NUS Neuroscience ACP Research Paper of the Quarter (Jul – Dec 2019) 
  • Long Service Award (10 years) (SingHealth, 2018)
  • Educational Travel Award (ACTRIMS, 2019)
  • Educational Travel Award (ECTRIMS Summer School, 2019)
  • Travel Award (1st Nordic Metabolomics Conference, 2018)
  • Research Training Fellowship Award, Overseas PhD (NMRC, 2016)
  • Outstanding Tutor Award (Yong Loo Lin School of Medicine, NUS, 2016)
  • MCI Research Scholarship Award (NMRC, 2015)
  • Best Registrar Award (SingHealth, 2015)

Research Interests

  • Neuroimmunology
  • Neuroinflammation
  • Biomarkers
  • Multi-omics

Publications

  • Yeo T, Bayuangga H, Augusto-Oliveira M, Sealey M, Claridge TDW, Tanner R, Leppert D, Palace J, Kuhle J, Probert F, Anthony DC. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model. J Neuroinflammation 2022;19, 252.
  • Yeo T, Probert F, Sealey M, Saldana L, Geraldes R, Höeckner S, Schiffer E, Claridge TDW, Leppert D, DeLuca G, Kuhle J, Palace J, Anthony DC. Objective biomarkers for clinical relapse in Multiple Sclerosis: A metabolomics approach. Brain Commun 2021;3(4):fcab240.
  • Probert F*, Yeo T*, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Kuhle J, Leppert D, Anthony DC. Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of MS from non-MS patients with CSF oligoclonal bands. Front Immunol 2022;12:811351. (*joint first authors)
  • Yeo T, Sealey M, Zhou Y, Saldana L, Loveless S, Claridge TDW, Robertson N, DeLuca G, Palace J, Anthony D, Probert F. A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Sci Rep 2020;10:12381.
  • Yeo T*, Probert F*, Jurynczyk M, Sealey M, Cavey A, Claridge TDW, Woodhall M, Waters P, Leite MI, Anthony DC, Palace J. Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modelling. Neurol Neuroimmunol Neuroinflamm. 2019 Oct 28;6(6):e626. (*joint first authors)

Refer to Google Scholar for full list of publications: https://scholar.google.com.sg/citations?user=BiAIDdEAAAAJ&hl=en

Research Trials

As Principal Investigator:

  • Neuroimmunology Longitudinal Singapore (NILONS) Study, Department of Neurology, NNI
  • Deciphering the relationship between the gut microbiome and metabolome with systemic and neuroinflammation in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and related neuroimmunological disorders, Department of Neurology, NNI
  • Longitudinal evaluation of immunogenic responses after COVID-19 vaccination in patients with Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and related neuroinflammatory disorders, Department of Neurology, NNI
  • Validity and reliability of the Fatigue Severity Scale in Multiple Sclerosis and Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorder population in Singapore (FAMNS), Department of Neurology, NNI
  • Prevalence of Central Nervous System Autoantibodies in Cryptogenic Epilepsy and Insights into Immunotherapy Treatment Effect (PACE), Department of Neurology, NNI
  • Validation of a Commercial Assay in the Detection of LGI1 and CASPR2 Antibodies, Department of Neurology, NNI